ATH434 is designed to block the aggregation of pathological proteins which are involved in neurodegeneration. Credit: Alterity Therapeutics.

Alterity Therapeutics has received the St. Vincent’s Hospital Melbourne Human Research Ethics Committee’s (HREC) approval to begin the Phase II clinical trial of ATH434 in Australia to treat multiple system atrophy (MSA).

The company has also opened patient enrolment at its first clinical trial site in Sydney.  

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The placebo-controlled, randomised, double-blind trial will assess ATH434’s efficacy and safety in early-stage MSA patients.

Nearly 60 adult patients are expected to be enrolled and will be given one of two doses of ATH434 or a placebo in the study.

In the trial, the impact of treatment with ATH434 on neuroimaging and protein biomarkers, including excess brain iron and aggregating α-synuclein, which are said to be crucial contributors to the pathology of MSA, will be assessed.

Alterity stated that the clinical endpoints will support the complete evaluation of the efficacy of ATH434, as well as the characterisation of pharmacokinetics and safety.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial participants will be treated for 12 months, which will offer a chance for identifying the variations in efficacy endpoints to optimise the Phase III trial design.

Alterity CEO David Stamler said: “We are thrilled to receive ethics approval and launch our first clinical trial site for enrolment in Australia.

“ATH434 is designed to slow the progression of MSA and we are eager to increase access to our study of this potential disease modifying treatment.

“Our Phase II programme has now received regulatory authorisation in five countries, with three locations actively recruiting participants in the trial.”

The oral agent, ATH434 has been designed to block the aggregation of pathological proteins involved in neurodegeneration.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact